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Emery–Dreifuss muscular dystrophyMutations in LMNA, which encodes A-type nuclear lamins, cause disorders of striated muscle that have as a
common feature dilated cardiomyopathy. We have demonstrated an abnormal activation of both the
extracellular signal-regulated kinase (ERK) and the c-Jun N-terminal kinase (JNK) branches of the mitogen-
activated protein kinase signaling cascade in hearts from LmnaH222P/H222P mice that develop dilated
cardiomyopathy. We previously showed that pharmacological inhibition of cardiac ERK signaling in these
mice delayed the development of left ventricle dilatation and deterioration in ejection fraction. In the present
study, we treated LmnaH222P/H222P mice with SP600125, an inhibitor of JNK signalling. Systemic treatment
with SP600125 inhibited JNK phosphorylation, with no detectable effect on ERK. It also blocked increased
expression of RNAs encoding natriuretic peptide precursors and proteins involved in the architecture of the
sarcomere that occurred in placebo-treated mice. Furthermore, treatment with SP600125 signiﬁcantly
delayed the development of left ventricular dilatation and prevented decreases in cardiac ejection fraction
and ﬁbrosis. These results demonstrate a role for JNK activation in the development of cardiomyopathy
caused by LMNA mutations. They further provide proof-of-principle for JNK inhibition as a novel therapeutic
option to prevent or delay the cardiomyopathy in humans with mutations in LMNA., College of Physicians and
t, 10th Floor, Room 508, New
12 305 6443.
n), am2434@columbia.edu
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Mutations in LMNA encoding A-type nuclear lamins are respon-
sible for at least three severe diseases involving striated muscles:
autosomal Emery–Dreifuss muscular dystrophy [1], limb girdle mus-
cular dystrophy type 1B [2], and dilated cardiomyopathy type 1A [3]. A
common feature of these disorders is dilated cardiomyopathy, which
is characterized by an age of onset generally in the third decade of life
and frequently associated with a progressive conduction system
disease leading to implantation of deﬁbrillators [4]. Affected indivi-
duals eventually develop heart failure, for which there is currently no
curative treatment, ultimately necessitating cardiac transplantation.
Identiﬁcation of LMNA mutations in patients with dilated
cardiomyopathy raised intriguing questions about the relationshipbetween A-type nuclear lamins and dilated cardiomyopathy, since
lamins are not known to contribute in force transmission or
generation in cardiomyocytes. The link between cardiomyopathy
and abnormalities in A-type lamins is poorly understood and only a
few hypotheses have been raised concerning pathophysiology. We
have recently reported an abnormal activation of the extracellular
signal-regulated kinase (ERK) and the c-Jun N-terminal kinase (JNK)
branches of the mitogen-activated protein kinase (MAP kinase)
signalling cascade in hearts of Lmna H222P knock-in mice, a model
of autosomal Emery–Dreifuss muscular dystrophy [5]. Male
LmnaH222P/H222P mice developed left ventricular (LV) dilatation
and depressed contractile function starting at approximately 8–
10 weeks of age and invariably developed LV dilatation and de-
creased cardiac contractility at 16 weeks of age with death typically
occurring between 16 and 36 weeks [6]. On the basis of our
observations that ERK and JNK are activated in these mice before
the onset of clinically detectable cardiomyopathy, as well as our
demonstration that lamin A variants that cause striated muscle
disease activate both of these protein kinases when expressed in
cultured cells, we hypothesized that abnormal activation of ERK and
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cardiomyopathy [5]. Recently, we showed that blocking ERK
signalling in male LmnaH222P/H222P mice, using a small molecule
inhibitor of extracellular signal-regulated kinase kinase (MEK) that
activates ERK, induced normal LV diameters and cardiac ejection
fraction (EF) at the age of 16 weeks, when placebo-treated mice had
signiﬁcant abnormalities in these parameters [7]. In the present
study, we sought to determine if pharmacological inhibition of JNK
signaling would similarly prevent or delay the development of
dilated cardiomyopathy in LmnaH222P/H222P mice. To test this
hypothesis, we treated LmnaH222P/H222P mice with SP600125, an
inhibitor of JNK.2. Methods
2.1. Mice
LmnaH222P/H222P mice were generated and genotyped as previous-
ly described [6]. Genotyping was performed by polymerase chain
reaction using genomic DNA isolated from tail clippings and oligo-
nucleotides with sequences 5′-cagccatcacctctcctttg-3′ and 5′-agcac-
cagggagaggacagg-3′. Mice were fed a chow diet and housed in a
disease-free barrier facility with 12-h/12-h light/dark cycles. The
Institutional Animal Care and Use Committee at Columbia University
Medical Center approved the use of animals and the study protocol.
The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996).2.2. JNK inhibitor
The anthrapyrazolone inhibitor of JNK, SP600125 (Calbiochem),
was dissolved in dimethyl sulfoxide (DMSO) (Sigma) at a concentra-
tion of 0.5 mg/ml and administered at a dose of 3 mg/kg/day for
5 days a week. The inhibitory activity of SP600125 is selective for all
JNK isoforms (IC50=40 nM for JNK-1 and JNK-2 and 90 nM for JNK-3)
[8]. The placebo consisted of DMSO alone and was delivered in the
same volume. Placebo and SP600125 were administered by intraper-
itoneal injection using a 27 5/8-gauge syringe. Treatmentwas initiated
when mice were 8 weeks of age and continued until 16 weeks of age.2.3. Thansthoracic echocardiography
At 16 weeks of age, mice were anesthetized with 1.5% isoﬂurane
in O2 and placed on a heating pad (37 °C). Echocardiography was
performed using a Visualsonics Vevo 770 ultrasound with a 30-MHz
transducer applied to the chest wall. Cardiac ventricular dimensions
and EF were measured in 2D mode and M-mode three times for the
number of animals indicated. A “blinded” echocardiographer (J.S.),
unaware of the genotype or treatment, performed the examinations
and interpreted the results.2.4. Histopathological analysis
Mice were sacriﬁced at 16 weeks of age after being examined
by echocardiography and freshly removed hearts were ﬁxed in 4%
formaldehyde for 48 hours, embedded in parafﬁn, sectioned at 5 µm,
and stained with Gomori's trichrome or hematoxylin and eosin. Rep-
resentative stained sections were photographed using a Microphot SA
(Nikon) light microscope attached to a Spot RT Slide camera (Diag-
nostic Instruments). Images were processed using Adobe Photoshop
CS (Adobe Systems).2.5. Protein extraction and immunoblotting
Heart tissue was homogenized in extraction buffer as previously
described [7]. Protein samples were subjected to SDS–PAGE, trans-
ferred to nitrocellulose membranes, and blotted with primary
antibodies against JNK (Santa Cruz), phosphorylated JNK (no. 9251;
Cell Signaling), phosphorylated c-Jun (no. Sc-822; Santa Cruz), ERK1/
2 (no. Sc-94; Santa Cruz), and phosphorylated ERK1/2 (no. 9101; Cell
Signaling). Secondary antibodies were horseradish peroxidase–
conjugated (Amersham). Recognized proteins were visualized by
enhanced chemiluminescence (ECL; Amersham). The signal generat-
ed using antibody against GAPDH was used as an internal control to
normalize the amounts of protein between immunoblots.
2.6. Quantitative real-time RT–PCR analysis
Total RNA was extracted using the RNeasy Isolation Kit (Qiagen)
as previously described [7]. cDNA was synthesized using Superscript
ﬁrst strand synthesis system according to the manufacturer's
instructions (Invitrogen) on total RNA. For each replicate in each
experiment, RNA from tissue samples of different animals was used.
Primers were designed correspond to mouse RNA sequences using
Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.
cgi) for Nppa (forward 5′-gcttccaggccatattggag-3′, reverse 5′-
ccctgcttcctcagtctgct-3′), Nppb (forward 5′-ggaccaaggcctcacaaaag-
3′, reverse 5′-tacagcccaaacgactgacg-3′),Myl4 (forward 5′-cccaagcct-
gaagagatgag-3′, reverse 5′-agacaacagctgctccacct-3′), Myl7 (forward
5′-tcaaggaagccttcagctgc-3′, reverse 5′-cggaacacttaccctcccg-3′),
Myh7 (forward 5′-tgcagcagttcttaaccac-3′, reverse 5′-tcgaggcttctg-
gaagttgt-3′), and JunD (forward 5′-atgtgcacgaaaatggaaca-3′, reverse
5′-cctgacccgaaaagtagctg-3′). The real-time RT–PCR reaction
contained iQ SYBR Green Super Mix (Bio-Rad), 200 nM of each
primer, and 0.2 µl of template in a 25-µl reaction volume. Ampliﬁ-
cation was carried out using the MyiQ Single-Color Real-Time PCR
Detection System (Bio-Rad) with an initial denaturation at 95 °C for
2 min followed by 50 cycles at 95 °C for 30 s and 62 °C for 30 s.
Relative levels of mRNA expression were calculated using the ΔΔCT
method [7]. Individual expression values were normalized by
comparison with Gapdh mRNA (forward 5′-tgcaccaccaactgcttag-3′,
reverse 5′-ggatgcagggatgatgttc-3′).
2.7. Statistical analysis
Results of immunoblots, real-time RT–PCR, and ﬁbrosis quantiﬁ-
cationwere compared using the Student unpaired t-test. Comparisons
of the echocardiographic parameters between DMSO-treated
LmnaH222P/H222P and Lmna+/+ mice and between SP600125-treated
and DMSO-treated LmnaH222P/H222P were performed using the
Student unpaired t-test; to validate these results, a nonparametric
test (Mann–Whitney) was performed and concordance was checked.
Statistical analyses were performed using GraphPad Prism software.
3. Results
3.1. Effect of SP600125 on JNK activity
Systemic administration of SP600125 to LmnaH222P/H222P mice
partially blocked phosphorylation of JNK in hearts as shown by
immunoblot (Fig. 1A). At 3 mg/kg/day (5 times a week), we did not
detect inhibition of phosphorylation of ERK in the hearts (Fig. 1A).
Quantiﬁcation of the immunoblot signals for JNK showed that DMSO-
treated LmnaH222P/H222P mice had a 2.5-fold increase of phosphory-
lated JNK expression compared to Lmna+/+mice but LmnaH222P/H222P
treated with SP600125 had a signiﬁcantly reduced level of phosphor-
ylated JNK similar to Lmna+/+ mice (Fig. 1A). Phosphorylation of the
downstream target, c-Jun, was also signiﬁcantly reduced by SP600125
Fig. 1. Treatment of male LmnaH222P/H222P mice with SP600125 inhibits phosphorylation of JNK signaling. (A) Representative immunoblots using antibodies against
phosphorylated JNK (p-JNK), total JNK, phosphorylated ERK1/2 (p-ERK1/2), and total ERK1/2 to probe proteins extracted from hearts from LmnaH222P/H222P mice treated
with SP600125 or DMSO. Blots of proteins extracted from hearts of Lmna+/+ mice are shown for comparison. Data in bar graphs show quantiﬁcation of phosphorylated
JNK compared with total JNK measured by scanning immunoblots and using ImageJ64 software. Values are means±standard errors for n=5 samples from different
animals per group. Comparison between DMSO-treated LmnaH222P/H222P and Lmna+/+ mice was performed using the Student unpaired t-test, ⁎⁎⁎Pb0.0005. Comparison
between SP600125-treated and DMSO-treated LmnaH222P/H222P was performed using the Student unpaired t-test, ‡‡Pb0.005. (B) Representative immunoblots using
antibody against phosphorylated cJun (p-cJun) to probe proteins extracted from hearts from LmnaH222P/H222P mice treated with SP600125 or DMSO. Blot of proteins
extracted from hearts of Lmna+/+ mice is shown for comparison. Antibody against GAPDH is used as a loading control. (C) Quantitative real-time RT–PCR showing the
expression of mRNA from JunD. Results from hearts from Lmna+/+ mice are shown for comparison. Bars indicate the fold overexpression of the indicated mRNA calculated
by the ΔΔCT method. Values are means±standard errors for n=5 samples from different animals per group. Reactions were performed in triplicate for each different RNA
sample. Comparison between DMSO-treated LmnaH222P/H222P and Lmna+/+ mice was performed using the Student unpaired t-test, ⁎⁎⁎Pb0.0005. Comparison between
SP600125-treated and DMSO-treated LmnaH222P/H222P was performed using the Student unpaired t-test, ‡‡Pb0.005.
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the efﬁcacy of the small molecule inhibitor in the heart at the given
dose.3.2. Effect of SP600125 on cardiac expression of natriuretic peptides
and myosin
A feature of dilated cardiomyopathy is the up-regulation of
natriuretic peptides [9]. The up-regulation of genes involved in
sarcomere organization also occurs in dilated cardiomyopathy [5]. In
hearts from male LmnaH222P/H222P mice, the expressions of NppA and
NppB mRNAs encoding natriuretic peptides precursors were signiﬁ-
cantly increased compared to Lmna+/+ mice (Fig. 2A). Similarly, the
expression ofMyl7 andMyl4mRNAs encoding myosin light chain and
the expression of Myh7 mRNA encoding myosin heavy chain were
signiﬁcantly increased compared to Lmna+/+ mice (Fig. 2B).SP600125-treated LmnaH222P/H222P mice had a signiﬁcantly decreased
cardiac expression ofMyl7,Myl4, Myh7, NppA, and NppB compared to
DMSO-treated LmnaH222P/H222P mice (Figs. 2A and B).3.3. Effect of JNK inhibition on cardiac function
Histopathological analysis of hearts at 16 weeks of age showed
that DMSO-treated LmnaH222P/H222P mice had an increase in ﬁbrotic
tissue compared to Lmna+/+ mice (Pb0.0005; Fig. 3A). As assessed by
quantiﬁcation of collagen staining, SP600125-treated LmnaH222P/H222P
mice had a statistically signiﬁcant decrease of ﬁbrosis compared to
DMSO-treated LmnaH222P/H222P (Pb0.05; Fig. 3A). Hence, treatment
with SP600125 prevents cardiac ﬁbrosis in LmnaH222P/H222P mice. To
conﬁrm the degree of ﬁbrosis, we further determined the expression of
Col1a1 and Col1a2 encoding type I collagen by quantitative real-time
RT–PCR. At 16 weeks of age, DMSO-treated LmnaH222P/H222P mice
Fig. 2. Treatment of male LmnaH222P/H222P mice with SP600125 inhibits expression of natriuretic peptides andmyosin chains. Quantitative real-time RT–PCR showing the expression
of (A) mRNAs from NppA and NppB genes encoding natriuretic peptide precursors A and B, respectively, and (B) mRNAs fromMyh7 encoding myosin heavy chain andMyl4 andMyl7
encoding myosin light chain. Results from hearts from Lmna+/+mice are shown for comparison. Bars indicate the fold overexpression of the indicated mRNA calculated by the ΔΔCT
method. Values are means±standard errors for n=5 samples from different animals per group. Reactions were performed in triplicate for each different RNA sample. Comparison
between DMSO-treated LmnaH222P/H222P and Lmna+/+ mice was performed using the Student unpaired t-test, ⁎Pb0.05, ⁎⁎Pb0.005, ⁎⁎⁎Pb0.0005. Comparison between SP600125-
treated and DMSO-treated LmnaH222P/H222P was performed using the Student unpaired t-test, ‡Pb0.05, ‡‡Pb0.005.
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compared to Lmna+/+mice (Fig. 3B). InDMSO-treated LmnaH222P/H222P
mice, Col1a1 and Col1a2mRNAs were increased by 3-fold compared to
Lmna+/+ mice (Fig. 3B). Treatment with SP600125 signiﬁcantly
lowered the expression of both Col1a1 and Col1a2mRNAs in the heart
of LmnaH222P/H222P mice compared to the DMSO-treated LmnaH222P/
H222P mice (Fig. 3B).
We recently reported alterations in nuclear morphology, including
abnormal elongation of nuclei, in cardiomyocytes of LmnaH222P/H222Pmice [7]. At 16 weeks of age, DMSO-treated LmnaH222P/H222P mice had
a signiﬁcant increase in nuclear length, compared to Lmna+/+ mice
(Fig. 4A). Cardiomyocyte nuclei in SP600125-treated LmnaH222P/H222P
mice had an overall length that was similar to those in Lmna+/+ mice
(Fig. 4A). Mean lengths of cardiomyocyte nuclei in placebo-treated
LmnaH222P/H222P mice were signiﬁcantly longer than in Lmna+/+mice
and SP600125-treated LmnaH222P/H222P mice (Fig. 4B).
Compared with Lmna+/+mice, LmnaH222P/H222P mice treated with
DMSO had signiﬁcant increases in LV end-diastolic and end-systolic
Fig. 3. Treatment with SP600125 prevents cardiac ﬁbrosis in LmnaH222P/H222P mice. (A) Representative heart tissue sections from LmnaH222P/H222P mice treated with SP600125
or DMSO stained with Gomori's trichrome are shown. Heart tissue section from Lmna+/+ mice is shown for comparison. Scale bar: 50 μm. Bar graph represents the
quantiﬁcation of ﬁbrotic area in hearts from mice. Micrographs (n=3) for each heart were processed (JMicroVision software), and blue staining ﬁbrotic tissue was quantiﬁed
(ImageJ64 software). Bars indicate the percentage of ﬁbrosis in heart from Lmna+/+ and LmnaH222P/H222P mice treated with SP600125 or DMSO. Values are means±standard
errors for n=3 mice per group. Comparison between DMSO-treated LmnaH222P/H222P and Lmna+/+ mice was performed using the Student unpaired t-test, ⁎⁎⁎Pb0.0005.
Comparison between SP600125-treated and DMSO-treated LmnaH222P/H222P was performed using the Student unpaired t-test, ‡Pb0.05. (B) Effect of SP600125 inhibitor on
cardiac expression of collagens genes in LmnaH222P/H222P mice. Bars indicate the expression of Col1a1 and Col1a2 in heart from Lmna+/+ and LmnaH222P/H222P mice treated with
SP600125 or placebo (DMSO). Values are means±standard errors for n=3 hearts. Comparison between DMSO-treated LmnaH222P/H222P and Lmna+/+ mice was performed
using the Student unpaired t-test, ⁎Pb0.05, ⁎⁎Pb0.005. Comparison between SP600125-treated and DMSO-treated LmnaH222P/H222P mice was performed using the Student
unpaired t-test, ‡Pb0.05, ‡‡‡Pb0.0005.
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fractional shortening (Table 1), consistent with what has been
described in previous studies [6,7]. We then analyzed the effects of
the JNK inhibitor compared to the placebo on echocardiographic
parameters. The analysis was performed with heart rates similar
between the two groups (358.47±81.75 beats/min for DMSO-
treated LmnaH222P/H222P mice and 355±80.77 beats/min for
SP600125-treated LmnaH222P/H222P mice). When treated with
SP600125, LmnaH222P/H222P mice had approximately 5% smaller
mean LV end-diastolic diameter, although the difference compared
to placebo-treatment mice did not reach statistical signiﬁcance. When
treated with SP600125, LmnaH222P/H222P mice had a 15% smaller mean
LV end-systolic diameter compared to DMSO-treated LmnaH222P/H222P
mice (Pb0.05). Systemic treatment with SP600125 had a positive
effect on cardiac function leading to an EF approximately 20% higher
than in DMSO-treated LmnaH222P/H222P mice (Pb0.005). Hence,treatment with SP600125 for 8 weeks prevented or delayed the
development of signiﬁcant cardiac contractile dysfunction in
LmnaH222P/H222P mice.
4. Discussion
Our results show that abnormal activation of the stress-induced
JNK signalling pathway contributes to the pathogenesis of cardiomy-
opathy caused by mutations in LMNA encoding A-type lamins. It
remains unclear how A-type lamins with amino acid substitutions
activate JNK signalling. Some investigators have hypothesized that
alterations in response to stress may underlie the development of
cardiac disease caused by LMNAmutation [10]. Abnormal responses to
stress in cardiomyocytes with abnormalities in A-type lamins could
therefore potentially have an impact on activation of JNK. This hy-
pothesis remains to be tested.
Fig. 4. Treatment with SP600125 prevents abnormal elongation of cardiomyocyte
nuclei in LmnaH222P/H222P mice. (A) Histological analysis of cross sections of hearts from
LmnaH222P/H222P mice treated with SP600125 or placebo (DMSO). Heart from Lmna+/+
micewas used for comparison. Sections are stainedwith hematoxylin and eosin. Yellow lines
with arrowheads demonstrate the measurement of nuclear length. Scale bar: 10 μm.
(B) Quantiﬁcation of nuclear elongation in cardiomyocytes frommice. Cardiomyocyte nuclei
are measured along the yellow lines with arrowheads. Bars indicate the length of
cardiomyocyte nuclei in the indicated hearts. Values are means±standard errors for
n=230cardiomyocytes. ComparisonbetweenDMSO-treated LmnaH222P/H222P and Lmna+/+
mice was performed using the Student unpaired t-test, ⁎⁎⁎Pb0.0005. Comparison between
SP600125-treated and DMSO-treated LmnaH222P/H222P mice was performed using the
Student unpaired t-test, ‡‡‡Pb0.0005.
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of JNK in vivo, using SP600125, prevents signiﬁcant cardiomyopathy in
male LmnaH222P/H222P mice at an age when placebo-treated controlshave detectable cardiac dysfunction. We recently reported that the
partial pharmacological blockade of ERK signalling for the same
duration in LmnaH222P/H222P mice of the same age similarly prevents
cardiomyopathy [7]. Data in our previous study [7] and our current
results show that inhibiting either the ERK or the JNK branches of the
MAP kinase signalling cascade prevents the re-expression of fetal genes
such as those encoding myosins, the up-regulation in expression of
natriuretic peptides, LV dilatation, and decreased cardiac contractility.
We have also shown that the JNK inhibitor prevents onset of cardiac
ﬁbrosis in 16-week-old LmnaH222P/H222P mice.
This preclinical study in mice assessed primary (LV dilatation, EF)
and secondary (expression of natriuretic factors) end points that are
used inmany humanclinical heart failure trials. Themeasurements of LV
functionweusedare strictly correlated toprognosis, and inmanyhuman
clinical trials, their behaviour parallels changes in mortality with
treatment [11]. For example, LV end-systolic volume is the major deter-
minant of survival in human subjects after recovery from myocardial
infarction and after coronary artery bypass grafting for impaired LV
function [12,13]. While mortality is a reasonable end point in phase III
clinical trials for advanced heart failure, it is rarely, if ever, used in the
initial drug assessmentphaseor in treatmentof subjectswith early heart
disease [11], as were both the case in our study. The effect of JNK
inhibition at later treatment onset, after the development of decreased
cardiac ejection fraction, is currently being evaluated in our laboratory,
asmany patientswill be diagnosed at an advance stage. Nonetheless, our
previous [7] and current results clearly provide proof-of-principle that
speciﬁc inhibitors that target both JNK and ERK signalling could prevent
or delay the onset of cardiomyopathy caused by LMNA mutations and
indicate that additional studies are warranted. Future studies of the
effects of ERK and JNK signalling pathway inhibitors on cardiac
conduction defects could also be interesting, given that early conduction
abnormalities usually occur in human subjects with LMNAmutations.
JNK has been shown to play a central role in tissue remodelling
through its ability to interact to AP-1-mediated transcription [14,15].
AP-1 function is regulated both through changes in the abundance of
its Jun and Fos components and posttranslational modiﬁcation by
phosphorylation [16]. Of interest, AP-1 modulates the regulation of
type I collagen [17,18]. This is consistent with our observation that
SP600125 decreased the expression of JunD mRNA as well as Col1a1
and Col1a2mRNAs in hearts of LmnaH222P/H222P mice. We also showed
that there was a markedly decreased amount of myocardial ﬁbrosis in
hearts of 16-week-old LmnaH222P/H222P mice treated with the JNK
inhibitor. This antiﬁbrotic action of SP600125 could be secondary to
the beneﬁcial effect on the cardiac structure and function.
Additional preclinical research should be performed before ini-
tiating clinical trials of ERK and JNK inhibition in human subjects with
cardiomyopathy caused by LMNA mutations. To resolve the possible
but unlikely issue that off-target effects are providing beneﬁts on
cardiomyopathy in LmnaH222P/H222P mice, these animals should be
treated with other drugs in these classes, such as JNK inhibitors of
different structure that recognize a different interaction site [19]. For
ERK signalling, several compounds of different structures that act at
various sites in the pathway are currently in clinical development and
several have already been used in human subjects [20]. The effects of
longer-term ERK and JNK inhibition on various tissues also need to be
examined in experimental animals, especially on skeletal muscle that
is often simultaneously affected in individuals with LMNA mutations
that cause cardiomyopathy [1,2].Conﬂict of interest
H.J.W. and A.M. are inventors on a pending PCT patent application
on methods for treating and/or preventing cardiomyopathies by ERK
and JNK inhibition ﬁled by the Trustees of Columbia University in the
City of New York.
Table 1
Echocardiographic data at 16 weeks of age for Lmna+/+ mice and LmnaH222P/H222P mice treated with DMSO or SP600125.
Genotype (treatment) n LVEDD (mm) LVESD (mm) IVSD (mm) EF (%) FS (%)
Lmna+/+ (no treatment) 13 3.35±0.09 2.00±0.09 0.72±0.02 76.82±2.01 44.21±1.77
LmnaH222P/H222P (DMSO) 15 3.59±0.09⁎ 2.68±0.14⁎⁎⁎ 0.65±0.03⁎ 56.89±2.87⁎⁎⁎ 29.70±1.87⁎⁎⁎
LmnaH222P/H222P (SP600125) 13 3.46±0.07 2.30±0.12‡ 0.72±0.02‡ 69.24±2.66‡‡ 38.70±2.05‡‡
LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; IVSD, interventricular septum diameter; EF, ejection fraction; FS, fractional shortening.
Values are means±standard errors.
Comparison between DMSO-treated LmnaH222P/H222P and Lmna+/+ mice was performed using the Student unpaired t-test, ⁎Pb0.05, ⁎⁎Pb0.005, ⁎⁎⁎Pb0.0005.
Comparison between SP600125-treated and DMSO-treated LmnaH222P/H222P was performed using the Student unpaired t-test and results validated by a nonparametric test (Mann–
Whitney), ‡Pb0.05, ‡‡Pb0.005.
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